The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables
Open accessAbstract
BACKGROUND European Organization for Research and Treatment of Cancer (EORTC) risk tables only included 171 patients treated with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE To evaluate the external validity of the EORTC tables in patients with NMIBC treated with BCG over 5-6 mo. DESIGN, SETTING, AND PARTICIPANTS Data on 1062 patients treated with BCG were analyzed. MEASUREMENTS Discrimination was assessed using the concordance index (c-index) and the prognostic separation index (PSEP). For calibration, probabilities of recurrence and progression obtained with the EORTC risk tables in our series were compared with those reported by the EORTC. RESULTS AND LIMITATIONS With respect to the discriminative ability of the EORTC model, c-index was similar to those reported in the EORTC series for recurrence. However, c-indices for progression in our series were lower than c-indices reported by Sylvester et al. [1]. Although PSEP in our series was lower than in the EORTC series for recurrence at 1 yr, similar results were found at 5 yr. Regarding progression, PSEP in our series was lower than in the EORTC series. Whilst a successful stratification of recurrence and progression probability at 1 and 5 yr was achieved using the EORTC tables in our series, model calibration showed lower risks of recurrence than those reported by Sylvester et al. [1] in all groups. For progression, lower risks were found in higher-risk groups. There are some limitations in the present study. A different distribution of patients was found, with higher proportions of primary grade 3 T1 tumors and tumors in situ than in the EORTC series. An additional limitation is that prior recurrence of the EORTC table was not included in our parameters. Consequently, two separate analyses were performed for recurrence. CONCLUSIONS The EORTC model successfully stratified recurrence and progression risks in our cohort. However, the discriminative ability of the EORTC tables decreased in our patients for progression. Moreover, these tables overestimated risks of recurrence and progression after BCG therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting performance of prognostic models in cancer: a review.
Mallett, S., Royston, P., Waters, R., Dutton, S., & Altman, D. G. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-21 · Cited by 195
Cited by
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu223 · Cited by 335
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature
Kluth, L. A., Black, P. C., Bochner, B. H., Catto, J., Lerner, S. P., Stenzl, A., Sylvester, R., Vickers, A. J., Xylinas, E., & Shariat, S. F. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.032 · Cited by 265
Palou, J., Sylvester, R. J., Faba, O. R., Parada, R., Peña, J. A., Algaba, F., & Villavicencio, H. (2012) · European Urology · doi:10.1016/j.eururo.2011.10.029 · Cited by 259
Metadata
- Authors
- Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Ojea, A., Portillo, J., Montesinos, M., Gonzalez, M., Pertusa, C., Rodriguez-Molina, J., Camacho, J. E., Rabadan, M., Astobieta, A., Isorna, S., Muntañola, P., Gimeno, A., Blas, M., & Martinez-Piñeiro, J. A.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 60
- Issue
- 3
- Pages
- 423-430
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2114706063
- Cited by
- 167
- References
- 1
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables. https://app.cochat.ai/papers/10.1016/j.eururo.2011.05.033
- The paper
- Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Ojea, A., Portillo, J., Montesinos, M., Gonzalez, M., Pertusa, C., Rodriguez-Molina, J., Camacho, J. E., Rabadan, M., Astobieta, A., Isorna, S., Muntañola, P., Gimeno, A., Blas, M., & Martinez-Piñeiro, J. A. (2011). The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables. European Urology. https://doi.org/10.1016/j.eururo.2011.05.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.